ACCESSWIRE
24 Jan 2023, 05:19 GMT+10
NEW YORK, NY / ACCESSWIRE / January 23, 2023 / Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ('Y-mAbs' or the 'Company') (NASDAQ:YMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980.
The investigation concerns whether Y-mAbs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On October 3, 2022, Y-mAbs issued a press release 'announc[ing] clinical data on the Company's product candidate OMBLASTYS® (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.' Among other data, Y-mAbs reported that 'Serious Adverse Events (‘SAE') was found in 40.6% of the patients and were mostly related to myelosuppression.'
On this news, Y-mAbs's stock price fell $1.14 per share, or 7.91%, to close at $13.28 per share on October 3, 2022.
Then, on October 26, 2022, the U.S. Food and Drug Administration ('FDA') posted briefing documents expressing concerns that the Biologics License Application for the Company's product candidate does not provide sufficient evidence of efficacy. Specifically, the FDA cited the fact that the Company submitted data from just a single center, single arm trial; that additional analyses conducted by the FDA to examine bias and results found that differences in survival cannot be reliably attributed to omburtamab; and that the application does not include reliable response rate data to provide supportive evidence of the treatment effect of omburtamab.
On this news, Y-mAbs's stock price fell $4.16 per share, or 27.42%, to close at $11.01 per share on October 26, 2022.
Then, on October 28, 2022, the FDA's Oncologic Drugs Advisory Committee voted unanimously against approving the Company's marketing application for omburtamab.
On this news, Y-mAbs's stock price fell $5.32 per share, or 59.57%, to close at $3.61 per share on October 31, 2022.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Contact:
Robert S. Willoughby
Pomerantz Law Firm, LLP
newaction@pomlaw.com
888-476-6529, ext. 7980
SOURCE: Pomerantz Law Firm, LLP
Get a daily dose of Baltimore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baltimore Star.
More InformationIn a report by The New York Times, it has been revealed that Israeli officials had obtained a detailed battle ...
NAYPYIDAW, Myanmar: Kyar Win, spokesperson for the Myanmar National Democratic Alliance Army, which launched a surprise offensive last month against ...
While Secretary of State Anthony Blinken has been frantically shuttling around the Middle East trying to stop the Israeli coflict ...
LESBOS, Greece: Greek authorities said a cargo ship sank off the island of Lesbos over the weekend during a storm, ...
COLUMBUS, Ohio: To stop the spread of bird flu, more than 1.3 million chickens will be killed on Ohio's Union ...
In a devastating turn of events, Israel's war on Gaza, sparked by Hamas's unprecedented attacks on October 7, has resulted ...
LONDON - Health experts and tobacco campaigners have strongly criticized New Zealand's decision to repeal laws that aimed to ban ...
NEW YORK, New York - The Dow Jones index was the standout on U.S. financial markets on Thursday with a ...
WASHINGTON D.C.: Despite the ongoing economic uncertainty, major discounts during the Thanksgiving weekend enticed U.S. shoppers, who spent some US$38 ...
BANGKOK, Thailand: This week, Thailand's Deputy Finance Minister Krisada Chinavicharana said after a weaker-than-expected third quarter, the country will downgrade ...
BEIJING, China: The country's commerce ministry said that during a meeting with Vietnamese Prime Minister Pham Minh Chinh in Ho ...
NEW YORK, New York - Retreating bond yields and a higher-then-expected GDP reading for the third quarter boosted U.S. stocks ...